Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
Status:
Not yet recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
Acute lymphoblastic leukemia (ALL) is the most frequent cancer in children, decreases in
adolescence and adulthood, and a second peak can be recorded starting from the 6th decade of
life. While the outcome in children is excellent, in the adolescent/adult population, the
prognosis, though improved over the decades, it is still unsatisfactory and novel
biologically-driven approaches are urgently needed. In this setting, thanks to the
introduction of genome wide technologies, it was possible to recognize specific subset of
ALL. Among those, the BCR/ABL1-like ALL are of extreme importance, since they are
characterized by an unfavourable outcome and, on the other hand, can benefit of a targeted
treatment, in particular with the pan-tyrosine kinase inhibitor ponatinib.
The primary objective is to evaluate the clinical response - in terms of MRD negativity - in
patients with a BCR/ABL1-like profile, according to the BCR/ABL1-like predictor tool, treated
with Ponatinib in combination with chemotherapy.